Dr. Agarwal's Health Care
- Market cap
- ₹ 15,099 Cr.
- P/E
- 102x
- P/B
- 7.33x
- 52-week range
- 401 – 567.75
- ROE
- 7%
- ROCE
- 11%
- Dividend yield
- 0%
- Debt / equity
- 0.53
- Sector
- Healthcare Services
- Industry
- Hospital
- Listed on
- NSE, BSE
About
Dr. Agarwal's Health Care Ltd is an India-based company, which operates as a health care institution. The Company is engaged in running, owning and managing eye care hospitals, optical, pharmacies, etc. and related services. It provides a comprehensive range of eye care services, including cataract, refractive and other surgeries; consultations, diagnoses and non-surgical treatments; and sells optical, contact lenses and accessories, and eye-care related pharmaceutical products. Its services include surgeries and consultations, diagnoses and non-surgical treatments. Its surgery services include cataract surgery, refractive surgery, and other surgery. Its consultations, diagnoses and non-surgical treatments offer doctor consultation services, diagnostic services for eye disorders along with non-surgical treatments, including retinal laser therapy and dry eye treatment. It provides a range of glasses, lenses, contact lenses and frames at its facilities.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Hospital: 41 companies →Dr. Agarwal's Health Care against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)102 against a typical 48.9: pricier than most peers (1st = cheapest).31st of 40
- Sales growth+26.1% against a typical +21.1% from a year earlier.15th of 34
- Profit growth+44.7% against a typical +13% from a year earlier.7th of 31
- Share price, 3 months−2.5% against a typical −10.9%.12th of 34
- Size₹ 15,099 Cr. market value against a typical ₹ 1,306.7 Cr. (1st = largest).9th of 36
Latest announcements
Exchange filings and their impact on the company.
- Eye Hospital merger effective Nov 1 simplifies group structure with no material change to consolidated scale.
Dr. Agarwal's Health Care said its amalgamation with Dr. Agarwal's Eye Hospital has been sanctioned by NCLT Chennai and will become effective on November 1, 2026, with April 1, 2026 as the appointed date. The board fixed November 18, 2026 as the record date for the share swap of 23 shares of Rs 1 each for every 2 shares of Rs 10 each held in the transferor company. The merger combines authorized capital and simplifies the group structure, with only a small net impact on consolidated earnings.
Credit ratings
Every rating action on file, newest first, including reaffirmations. Open a row for the agency's reasoning. All credit rating updates
High safety
Rated AA- by ICRA- No warnings from the agency.
| Agency | Current rating | Outlook | As of |
|---|---|---|---|
| CRISIL | Withdrawn | — | 15 Jun 2026 |
| ICRA | [ICRA]AA- /[ICRA]A1+ | Stable | 23 Feb 2026 |
| Rating | Details | |||||
|---|---|---|---|---|---|---|
| 15 Jun 2026 | Withdrawn | — | — | CRISIL | ₹ 370 Cr. | |
| 23 Feb 2026 | Reaffirmed | [ICRA]AA- /[ICRA]A1+ | — | ICRA | ₹ 200 Cr. | |
| 9 Dec 2025 | ▲ Upgrade1 notch | Crisil A+ → Crisil AA- | — | CRISIL | ₹ 370 Cr. | |
| 14 Oct 2025 | New rating | [ICRA]AA- /[ICRA]A1+ | — | ICRA | ₹ 100 Cr. | |
| 4 Sep 2025 | Reaffirmed | Crisil A+ | — | CRISIL | ₹ 370 Cr. |
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 5 Nov 2026Upcoming | Financial Results | To consider and approve the financial results for the period ended September 30, 2026 |
| 4 Aug 2026 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2026 |
| 21 May 2026 | Financial Results | To consider and approve the financial results for the period ended March 31, 2026 |
| 3 Feb 2026 | Financial Results | To consider and approve the Unaudited (Standalone & Consolidated) Financial Results of the Company for the quarter and half year ended December 31, 2025 |
| 30 Oct 2025 | Financial Results | To consider and approve the unaudited financial results (standalone and consolidated) for the period ended September 30, 2025 |
| 12 Aug 2025 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2025 |
| 28 May 2025 | Financial Results | To consider and approve the audited financial results (standalone and consolidated) for the quarter and year ended March 31, 2025 |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 333 | 349 | 403 | 417 | 431 | 460 | 487 | 499 | 530 | 564 | 614 |
| Expenses | 244 | 241 | 300 | 310 | 316 | 329 | 360 | 363 | 386 | 403 | 444 |
| Operating Profit | 89 | 108 | 104 | 107 | 115 | 131 | 128 | 136 | 144 | 161 | 170 |
| OPM % | 27% | 31% | 26% | 26% | 27% | 28% | 26% | 27% | 27% | 29% | 28% |
| Other Income | 12 | 20 | 6 | 12 | 13 | 13 | 13 | 8 | 11 | 14 | 6 |
| Interest | 22 | 27 | 27 | 28 | 28 | 25 | 25 | 23 | 21 | 22 | 23 |
| Depreciation | 43 | 47 | 56 | 57 | 58 | 60 | 63 | 68 | 69 | 77 | 78 |
| Profit before tax | 36 | 54 | 27 | 33 | 41 | 59 | 54 | 54 | 65 | 77 | 75 |
| Tax % | 37% | 24% | 33% | 36% | 31% | 27% | 29% | 32% | 33% | 35% | 27% |
| Net Profit | 23 | 41 | 18 | 21 | 28 | 43 | 38 | 36 | 44 | 50 | 55 |
| EPS in Rs | — | — | — | — | 0.72 | 1.03 | 0.95 | 0.94 | 1.07 | 1.25 | 1.43 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- —
- 5 Years
- 35%
- 3 Years
- 27%
- TTM
- 23%
- 10 Years
- —
- 5 Years
- 34%
- 3 Years
- 13%
- TTM
- 43%
- 10 Years
- —
- 5 Years
- —
- 3 Years
- —
- TTM
- —
- 10 Years
- —
- 5 Years
- 8%
- 3 Years
- 6%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Dr. Agarwal's Health Care | ₹ 476.35 | ₹ 15,099 Cr. | 102x | 7.3x | 7% | — |
| Apollo Hospitals Enterprise | ₹ 7,730.00 | ₹ 1,09,249 Cr. | 64.9x | 13.4x | 22% | 7.8% |
| Max Healthcare Institute | ₹ 815.00 | ₹ 79,325 Cr. | 71.3x | 9.9x | 14.3% | 17.2% |
| Fortis Healthcare | ₹ 712.90 | ₹ 53,821 Cr. | 67.2x | 7.2x | 11.1% | 11.7% |
| Aster DM Healthcare | ₹ 644.75 | ₹ 56,272 Cr. | 101.6x | 9.2x | 9.7% | 9.2% |
| Narayana Hrudayalaya | ₹ 1,646.90 | ₹ 33,586 Cr. | 47.5x | 9x | 19.9% | 10.3% |
Management
- Adil Agarwal
- Whole Time Director, Chief Executive Officer
- Anosh Agarwal
- Whole Time Director, Chief Operating Officer
- Thanikainathan Arumugam
- Vice President - Corporate Affairs, Company Secretary, Compliance Officer
Prices are delayed and for information only. Nothing on this page is investment advice.